NewAmsterdam Pharma N.V.

17.52
0.25 (1.45%)
At close: Apr 24, 2025, 3:59 PM

NewAmsterdam Pharma Statistics

Share Statistics

NewAmsterdam Pharma has 109.82M shares outstanding. The number of shares has increased by 22.04% in one year.

Shares Outstanding 109.82M
Shares Change (YoY) 22.04%
Shares Change (QoQ) 2.79%
Owned by Institutions (%) 99.99%
Shares Floating 61.05M
Failed to Deliver (FTD) Shares 448
FTD / Avg. Volume 0.04%

Short Selling Information

The latest short interest is 5.34M, so 4.86% of the outstanding shares have been sold short.

Short Interest 5.34M
Short % of Shares Out 4.86%
Short % of Float 7.32%
Short Ratio (days to cover) 4.96

Valuation Ratios

The PE ratio is -10.04 and the forward PE ratio is -9.83. NewAmsterdam Pharma's PEG ratio is -0.53.

PE Ratio -10.04
Forward PE -9.83
PS Ratio 53.22
Forward PS 2.7
PB Ratio 3.2
P/FCF Ratio -15.23
PEG Ratio -0.53
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for NewAmsterdam Pharma.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.08, with a Debt / Equity ratio of 0.

Current Ratio 8.08
Quick Ratio 8.08
Debt / Equity 0
Debt / EBITDA 0
Debt / FCF 0
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $670.04K
Profits Per Employee $-3.55M
Employee Count 68
Asset Turnover 0.05
Inventory Turnover n/a

Taxes

Income Tax -1K
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -18.28% in the last 52 weeks. The beta is 0, so NewAmsterdam Pharma's price volatility has been lower than the market average.

Beta 0
52-Week Price Change -18.28%
50-Day Moving Average 19.88
200-Day Moving Average 19.9
Relative Strength Index (RSI) 45.12
Average Volume (20 Days) 1.01M

Income Statement

In the last 12 months, NewAmsterdam Pharma had revenue of 45.56M and earned -241.6M in profits. Earnings per share was -2.56.

Revenue 45.56M
Gross Profit 45.56M
Operating Income -176.29M
Net Income -241.6M
EBITDA -241.49M
EBIT -241.6M
Earnings Per Share (EPS) -2.56
Full Income Statement

Balance Sheet

The company has 771.74M in cash and 448K in debt, giving a net cash position of 771.29M.

Cash & Cash Equivalents 771.74M
Total Debt 448K
Net Cash 771.29M
Retained Earnings 0
Total Assets 864.62M
Working Capital 756.5M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -158.56M and capital expenditures -672K, giving a free cash flow of -159.24M.

Operating Cash Flow -158.56M
Capital Expenditures -672K
Free Cash Flow -159.24M
FCF Per Share -1.69
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -386.91% and -530.25%.

Gross Margin 100%
Operating Margin -386.91%
Pretax Margin -530.25%
Profit Margin -530.25%
EBITDA Margin -530%
EBIT Margin -386.91%
FCF Margin -349.49%

Dividends & Yields

NAMS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for NAMS is $42, which is 139.7% higher than the current price. The consensus rating is "Buy".

Price Target $42
Price Target Difference 139.7%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Scores

Altman Z-Score 10.19
Piotroski F-Score 3